First Line Treatment with Napabucasin plus Nab-Paclitaxel and Gemcitabine
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

First Line Treatment with Napabucasin plus Nab-Paclitaxel and Gemcitabine

Sponsor: Boston Biomedical, Inc.

First line treatment adding Napabucasin to standard of care chemotherapy combination Nab-Paclitaxel and Gemcitibine for patients with metastatic pancreatic cancer. Napabucasin is a novel, orally administered agent that works by inhibiting the renewal and survival of cancer stem cells.